If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
214
results.
Updated on
16/02/2026 [06:51:00]
Results 150 to 175 of 214
Absstract of: WO2026030275A1
The present disclosure relates to RNA molecules encoding an EBV polypeptide. The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the treatment and/or prevention of infectious mononucleosis, and other diseases associated with EBV infection.
Absstract of: US20260034198A1
A nanozyme-loaded nucleus pulposus matrix hydrogel microsphere is provided. A simple-to-prepare LOX—MnO2 nanozyme is provided, and the simple-to-prepare LOX—MnO2 nanozyme is loaded onto the GDNP, and an LOX—MnO2-loaded and glucose-enriched decellularized nucleus pulposus hydrogel microsphere, namely the nanozyme-loaded nucleus pulposus matrix hydrogel microsphere is formed through a new two-stage temperature-controlling microfluidic system.
Absstract of: US20260034230A1
The present invention provides, in part, protein-drug conjugates comprising an anti-transferrin receptor (e.g., human transferrin receptor) antigen-binding protein (e.g., scFv, Fab) conjugated to a molecular cargo (e.g., polynucleotides, liposomes or lipid nanoparticles) for delivery of the molecular cargo to a targeted tissue (e.g., brain or muscle). Methods for treating various diseases or disorders, such as neurological diseases or muscular diseases, with the conjugates are provided.
Absstract of: US20260034071A1
The present disclosure is based, at least in part, on the discovery that high-purity PEG lipids exhibit superior physical and biological properties, particularly when used in lipid nanoparticle (LNP) formulations. Therefore, the present disclosure provides PEG lipids at a recommended purity, e.g., for use in formulations, such as LNP formulations. The present disclosure also provides LNPs comprising the high-purity PEG lipids, and methods for delivering therapeutic agents to a subject using the same.
Absstract of: US20260034070A1
The disclosure relates to block copolymer nanoparticles for in vivo screening and for in vivo therapeutic delivery, and methods thereof. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering nucleotides.
Absstract of: US20260034236A1
A drug complex may include a target recognition molecule bonded to a copolymer X including structural units of (A), (B), and (C):R1, R2, and R3 being independently H or C1-3 alkyl, R4 being C1-3 alkyl, R5 being H, C1-18 alkyl, 3- to 8-membered cycloalkyl optionally being substituted, adamantyl, C6-18 aryl optionally being substituted, or 5- to 10-membered heteroaryl group optionally being substituted, X1, X2, and X3 being independent O, S, or N—R7, R6 being H, leaving group, or linker, R7 being H or C1-3 alkyl group, m being 1 to 100, and n being 0 to 3.
Absstract of: US20260035338A1
Provided are an amino lipid compound for preparing a lipid nanoparticle for delivering an active ingredient and a preparation method therefor, a lipid nanoparticle and a pharmaceutical composition containing the amino lipid compound, and the use thereof.
Absstract of: US20260034072A1
Described herein are compositions and methods for treating peripheral artery diseases, including a composition comprising a nanoparticle defining an interior volume and an exterior surface; a payload disposed within the interior volume of the nanoparticle; and a cellular membrane coating disposed on or encapsulating the exterior surface of the nanoparticle; wherein the cellular membrane coating comprises an ICAM1 binding ligand.
Absstract of: US20260034172A1
The present invention provides compositions comprising energy (e.g., light) absorbing submicron particles (e.g., microparticles comprising a core, a metal shell, and a metal/dielectric interface) and methods for delivering such particles via topical application.
Absstract of: US20260034168A1
An immuno-nanoparticle construct for use in therapeutic applications includes a nanocarrier, a stimulator of interferon (IFN) genes (STING) pathway agonist, and a toll-like receptor 4 (TLR4) agonist, wherein the STING pathway agonist and the TLR4 agonist are co-loaded in the nanoparticle carrier.
Absstract of: WO2026023606A1
The main purpose of the present invention is to develop a drug delivery system capable of suitably delivering a drug to the heart and/or the diaphragm. The present invention provides: particles for delivering a drug to the heart and/or the diaphragm, the particles having a boronic acid group as a target directional site; and a pharmaceutical composition or the like comprising said particles for delivering a drug.
Absstract of: CN120813597A
The present invention relates to oligonucleotides encoding metalloproteinase tissue inhibitor (TIMP) proteins, methods of treating diseases and medical conditions associated with insufficient presence of extracellular matrix proteins, the use of said oligonucleotides in such treatment, and pharmaceutical compositions and medical devices comprising such oligonucleotides.
Absstract of: US20260034069A1
The disclosure relates to block copolymer nanoparticles for in vivo therapeutic delivery, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering nucleotides that encode polypeptides.
Absstract of: AU2026200249A1
750152AUDIV1 3133692.v1 The present disclosure relates to compositions and methods that enable the formation of pharmaceutically relevant particles that can be used for therapy. In particular, the methods disclosed herein allow the controlled formation of circular particles having low internal void spaces comprising bioactive therapeutic agents. 750152AUDIV1 an a n v
Absstract of: WO2026030286A1
Particles are provided that include a liposome having a negatively charged outer surface and a lipid-drug conjugate, a first layer of cationic polymer such as poly-L-arginine (PLR), that is non-covalently associated with the negatively charged outer surface of the liposome, and a second layer having a mixture of an anionic polymer and polyethylene glycol modified anionic polymer that is non-covalently associated with the first layer. The particles can be formulated as pharmaceutical compositions that are useful in methods that target neurological disorders such as brain tumors and other neurological diseases, and that can deliver and/or transport therapeutic drugs across the blood brain barrier.
Absstract of: WO2026028149A1
The present disclosure provides gRNAs for editing SERPINA1 and combinations of such gRNAs, nucleic acids encoding such gRNAs, vectors comprising such nucleic acids, RNPs comprising such gRNAs and endonucleases, pharmaceutical compositions comprising any of the foregoing, and kits comprising any of the foregoing. The present disclosure further provides methods related to such gRNAs, including methods of manufacturing, methods of effecting SERPINA1 gene editing, and methods of preventing, treating, or ameliorating a symptom of a target disease, disorder, or condition such as A1ATD.
Absstract of: WO2026030568A1
Disclosed are branched poly(beta-amino ester) (PBAE) comprising a backbone having a ratio of diacrylate monomers and triacrylate monomers or diacrylate and tetraacrylate monomers, an amine sidechain, and an amine endgroup, and a nucleic acid, which are useful for the delivery of biomolecules, including the intracellular delivery of nucleic acids, which can be applied to almost any disease, ranging from cancer, to autoimmune diseases, to ocular diseases, to genetic disorders. These materials are particularly advantageous and enabled for delivery of mRNA and DNA to cells, including human cells. Compared to other PBAE nanoparticles, the disclosed NPs are smaller, more monodisperse, and more efficient at delivery and are useful and translatable as therapeutics.
Absstract of: WO2026030374A1
Provided herein is an ionizable lipid and a lipid nanoparticle composition including the ionizable lipid. The ionizable lipid and lipid nanoparticle composition are hypoxia responsive. Provided herein are also methods of delivering an agent to hypoxic tissue and treating disorders associated with hypoxia using the ionizable lipid and lipid nanoparticle composition. Such methods include treatment of placental related disorders.
Absstract of: WO2026029597A1
The present invention relates to a lipid nanoparticle composition containing a novel sterol lipid or a derivative thereof. The novel sterol lipid compound can replace part or all of the cholesterol, which is essential for the manufacture of lipid nanoparticles, so that the lipid nanoparticles are efficiently delivered to tissues other than the liver, thereby being able to be advantageously used in the development of gene therapeutic agents for various indications.
Absstract of: WO2026029591A1
Provided is a transition metal dichalcogenide (TMD) composite, wherein the transition metal dichalcogenide (TMD) is in the form of a nanosheet, a fatty acid is bonded to the transition metal dichalcogenide (TMD) nanosheet, and the expression type of macrophages is determined according to a combination of the transition metal dichalcogenide and the fatty acid.
Absstract of: WO2026029593A1
Provided is a transition metal dichalcogenide (TMD) composite, wherein a TMD is in the form of a nanosheet, a fatty acid is conjugated to the TMD nanosheet, and the phenotype of macrophages is determined according to a combination of the TMD and the fatty acid.
Absstract of: WO2026029046A1
The present invention provides: a urea or carbamate lipid having a cyclic group in a side chain; lipid nanoparticles containing the lipid as a constituent component; and a pharmaceutical composition thereof. The present inventors have found a urea or carbamate lipid having a cyclic group in a side chain, and urea or carbamate lipid nanoparticles containing the lipid as a constituent component. It has been found that the lipid nanoparticles can express a protein in cells.
Absstract of: WO2026026869A1
The present invention designs and synthesizes a class of ionizable lipids. A lipid nanoparticle delivery system composed thereof can be used to efficiently and safely deliver nucleic acid drugs such as DNA and RNA, or small-molecule drugs, and not only has good encapsulation efficiency and stability, but also exhibits good safety and clearance rate in animals. They provide good delivery performance for nucleic-acid therapeutics or prophylactics, and have broad application prospects in fields related to drug delivery.
Absstract of: WO2026026705A1
An atorvastatin calcium albumin nanoparticle, and a preparation method therefor and the use thereof. The atorvastatin calcium albumin nanoparticle consists of atorvastatin calcium and serum albumin in a mass ratio of 1:3-1:10. The preparation method comprises: adding absolute ethanol to atorvastatin calcium to obtain an organic phase, adding deionized water to serum albumin and adjusting the pH to obtain an aqueous phase, adding the organic phase in a dropwise manner to the aqueous phase, adding a glutaraldehyde solution for cross-linking, removing anhydrous ethanol, performing centrifugation, and collecting the lower precipitate layer to obtain the atorvastatin calcium albumin nanoparticle.
Nº publicación: WO2026026697A1 05/02/2026
Applicant:
CHINA MEDICAL UNIV [CN]
\u4E2D\u56FD\u533B\u79D1\u5927\u5B66
Absstract of: WO2026026697A1
A simvastatin albumin nanoparticle and preparation and use thereof. The simvastatin albumin nanoparticle is composed of simvastatin and serum albumin, wherein the mass ratio of simvastatin to serum albumin is 1:10-20. The simvastatin albumin nanoparticles are prepared by means of a nano-emulsification solvent volatilization method. The preparation method specifically comprises the preparation of an O/W emulsion and the preparation of albumin nanoparticles. The prepared nanoparticles have an average particle size of less than 500 nm, a polydispersity coefficient of less than 0.5, and an encapsulation efficiency of greater than 70%. The surface of the particles is negatively charged, and the zeta potential thereof is -31.25 mV. The nanoparticles can selectively target tumor cells, and exhibit different degrees of inhibitory effects on breast cancer, liver cancer, ovarian cancer, and colorectal cancer, with the strongest inhibitory effect observed on colorectal cancer.
BOPI
Electronic site
